Denali’s Avlayah Reduces CSF Heparan Sulfate by 91% in Phase 1/2 Trial for MPS II
Denali’s Avlayah reduced cerebrospinal fluid heparan sulfate by 91% in a Phase 1/2 trial for pediatric Hunter syndrome patients.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Hunter Syndrome
FDA Greenlights Avlayah (tividenofusp alfa-eknm) for Hunter Syndrome in Specific Patients on March 24
The FDA approved Avlayah (tividenofusp alfa-eknm) for treating neurologic Hunter syndrome in pediatric patients weighing at least 5 kg.
Read More